within Pharmacolibrary.Drugs.ATC.A;

model A10BK02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.65,
    Cl             = 0.0002033333333333333,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.119,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 19.8,            
    Vdp             = 0.482,
    k12             = 67.8,
    k21             = 67.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BK02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the treatment of type 2 diabetes mellitus in adults, improving glycemic control by reducing renal glucose reabsorption and promoting urinary glucose excretion. It is an approved, widely used oral antidiabetic agent.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers, both male and female, following a single 300 mg oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Devineni, D, et al., &amp; Mamidi, RN (2015). Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants. <i>Clinical pharmacology in drug development</i> 4(4) 295–304. DOI:<a href=\"https://doi.org/10.1002/cpdd.162\">10.1002/cpdd.162</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27136910/\">https://pubmed.ncbi.nlm.nih.gov/27136910</a></p></li><li><p>Hu, W, et al., &amp; Liu, Z (2020). Pharmacokinetics and bioequivalence of two oral formulations of canagliflozin after single-dose administration in healthy Chinese subjects . <i>International journal of clinical pharmacology and therapeutics</i> 58(1) 57–65. DOI:<a href=\"https://doi.org/10.5414/CP203437\">10.5414/CP203437</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31347489/\">https://pubmed.ncbi.nlm.nih.gov/31347489</a></p></li><li><p>Frampton, JE (2018). Empagliflozin: A Review in Type 2 Diabetes. <i>Drugs</i> 78(10) 1037–1048. DOI:<a href=\"https://doi.org/10.1007/s40265-018-0937-z\">10.1007/s40265-018-0937-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29946963/\">https://pubmed.ncbi.nlm.nih.gov/29946963</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BK02;
